Download Files:
Gardiquimod
$40 – $140
Products Details
Product Description
– Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM[1][2].
Web ID
– HY-103697
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C17H23N5O
References
– [1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306.
CAS Number
– 1020412-43-4
Molecular Weight
– 313.40
Compound Purity
– 98.0
SMILES
– OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N
Clinical Information
– No Development Reported
Research Area
– Cancer; Infection
Solubility
– DMF : ≥ 20 mg/mL|DMSO : ≥ 20 mg/mL|Ethanol : ≥ 12 mg/mL
Target
– HIV;Toll-like Receptor (TLR)
Isoform
– HIV-1;TLR7;TLR8
Pathway
– Anti-infection;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
